Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : 2026 TeoTwawKi ... 2032 Darkest Interregnum -- Ignore unavailable to you. Want to Upgrade?

To: TobagoJack who wrote (151907)	12/6/2019 8:12:50 AM
From: Logain Ablar	Read Replies (1) \| Respond to of 219356

TJ: Along the Alzheimer theme: 10 minute video and the article below it. fortune.com

To: TobagoJack who wrote (151907)	12/6/2019 9:01:33 AM
From: ggersh	Respond to of 219356

Let us watch and wait for the brief ;-)

To: TobagoJack who wrote (151907)	12/6/2019 10:10:16 AM
From: Julius Wong	Respond to of 219356

Alzheimer’s Drug BIIB and other companies: AVXL, BHVN

To: TobagoJack who wrote (151907)	12/7/2019 8:02:24 AM
From: THE ANT	1 Recommendation Recommended By Horgad Read Replies (1) \| Respond to of 219356

Read Bredesens the end Of Alzheimer's.Eat less than 15 grams of sugar a day, make carbs less than 20% of your diet and put all your eating into a 4-8 hour period. You will not get Alzheimer's or Vascular disease

To: TobagoJack who wrote (151907)	12/7/2019 9:43:06 AM
From: Pogeu Mahone	1 Recommendation Recommended By marcher Read Replies (1) \| Respond to of 219356

That drug is a loser. If the developers cannot determine if it helps it does not! Please do not give false hope to millions at ridiculous expense where a placebo wouldl work as well. I believe Biogen has the muscle to get this approved. If approved the FDA should be shot. How could Biogen's data hold up? After at least 5 years of research Biogen says this: 4 December 2019, 23:00 GMT+8 Biogen Inc. stunned Alzheimer’s researchers in March when it said its highly awaited Alzheimer’s treatment aducanumab was unlikely to work. Than this 6 months later Biogen Explains How Its Alzheimer’s Drug Went From Poor to Promising BY ALICE PARK DECEMBER 6, 2019 It doesn’t happen often—in fact, hardly ever—that a company decides to stop studying a promising drug it’s developing and then a few months later asks the Food and Drug Administration (FDA) to consider approving it. But that’s exactly what occurred with aducanumab, an Alzheimer’s drug being developed by U.S. pharmaceutical company Biogen and its partner, Eisai, a Japanese pharma outfit. The surprising reversal has left patients, researchers and doctors with a lot of questions—especially since the drug is the first one to, if approved, treat the root causes of Alzheimer’s disease, which affects more than five million people in the U.S. This week, at the Clinical Trials on Alzheimer’s Disease conference in San Diego, Biogen tried to provide some answers in its first detailed public disclosure of the data on its aducanumab study, but the analysis is complex. RELATED STORIES